Takeda Pharmaceutical Company (4502) investor relations material

Executive summary

• CEO transition completed, with Julie Kim succeeding Christophe Weber after a decade of transformation into a focused global R&D-driven biopharma company.

• FY2025 delivered solid results with core revenue of JPY 4,505.7B (-2.6% at CER), core operating profit of JPY 1,172.5B (-0.9% at CER), and core EPS of JPY 517 (+3.1% at CER), supported by OPEX savings offsetting VYVANSE generic erosion.

• Three late-stage assets—oveporexton, rusfertide, and zasocitinib—delivered positive phase III results and are positioned for regulatory approval and commercial launch in the next 12 months.

• Growth & Launch products grew 4.5% at CER, now representing over 50% of total revenue.

• Robust late-stage pipeline with multiple NMEs and lifecycle management opportunities.

Financial highlights

• Core revenue: JPY 4,505.7B (-2.6% at CER); core operating profit: JPY 1,172.5B (-0.9% at CER); core EPS: JPY 517 (+3.1% at CER).

• Reported operating profit rose 19.3% to JPY 408.8B, reflecting lower amortization and restructuring costs.

• Net profit attributable to owners surged 77.7% to JPY 191.8B.

• Adjusted free cash flow was JPY 684.5B, after a $1.2B upfront payment for an oncology partnership.

• Adjusted net debt/adjusted EBITDA improved to 2.6x.

Outlook and guidance

• FY2026 revenue forecast: JPY 4,640.0B (+3.0% year-over-year); core operating profit: JPY 1,160.0B (-1.1%); core EPS: JPY 472 (-8.7%).

• Management guidance at CER: low-single digit % decline in core revenue, 5–8% decline in core operating profit, mid-teens % decline in core EPS.

• Free cash flow outlook stable at JPY 650–750B; annual dividend to increase to JPY 204 per share.

• Horizon One (2–3 years): focus on launching three new products, protecting margins, and returning to revenue growth.

• Substantial investments planned in new product launches and R&D, partially offset by transformation program savings.